Paid Clinical Trials Grand Rapids
Discover 223 paid clinical trials in Grand Rapids, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Adaptive InterventionsTesting Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
Sponsor:
University of Michigan
Location:
Code:
NCT05457985
Conditions
PTSD
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Prolonged Exposure for Primary Care (PE-PC)
Full Prolonged Exposure
Clinician Supported PTSD Coach App
IDE196 & CrizotinibIDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma
Sponsor:
IDEAYA Biosciences
Location:
Code:
NCT05987332
Conditions
Metastatic Uveal Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
IDE196
Crizotinib
Pembrolizumab
Ipilimumab
Nivolumab
Vepdegestrant & PF-07220060A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Sponsor:
Pfizer
Location:
Code:
NCT06206837
Conditions
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
vepdegestrant
PF-07220060
Rilvegostomig & Fluoropyrimidine & Trastuzumab DeruxtecanA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Sponsor:
AstraZeneca
Location:
Code:
NCT06764875
Conditions
HER2-positive Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Rilvegostomig
Trastuzumab deruxtecan
Trastuzumab
Pembrolizumab
5-fluorouracil
LY3962673MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06586515
Conditions
Pancreatic Ductal Adenocarcinoma
Non-small Cell Lung Cancer
Colorectal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
LY3962673
Cetuximab
Gemcitabine
nab-paclitaxel
Oxaliplatin
BelumosudilA Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
Sponsor:
Sanofi
Location:
Code:
NCT06082037
Conditions
Lung Transplant Rejection
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Belumosudil
Azithromycin
Placebo
BNT317Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Sponsor:
BioNTech SE
Location:
Code:
NCT06750185
Conditions
Advanced Solid Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BNT317 DL1
BNT317 DL2
BNT317 DL3
BNT317 DL4
BNT317 DL5 (intermediate)
GORE® EXCLUDER®Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
Sponsor:
W.L.Gore & Associates
Location:
Code:
NCT06218875
Conditions
AAA - Abdominal Aortic Aneurysm
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
QTX3046QTX3046 in Patients with KRAS G12D Mutations
Sponsor:
Quanta Therapeutics
Location:
Code:
NCT06428500
Conditions
Advanced Solid Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
QTX3046
Cetuximab
Islatravir & LenacapavirStudy to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
Sponsor:
Gilead Sciences
Location:
Code:
NCT06630299
Conditions
HIV-1-Infection
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
ISL/LEN
Antiretroviral Combinations